BO
Blue Owl Healthcare Opportunities
Blue Owl Healthcare Opportunities is a Series A to Series D stage investment firm. It has made 16 investments. 61% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Average disclosed round size is $195.6M (across 21 rounds with reported amounts).
Portfolio
16
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Team
KR
Kevin Raidy
Senior Managing Director
RS
Robert Sine
Managing Director
TA
Tim Anderson
Managing Director
SC
Sara Clarke
Biotech Venture Capital
WK
Wai Kit Ma
Investor
KM
Kevin McGowan
Biotech VC
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
23 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Mirador Tx | Series B | $250M | Jan 2026 |
 Mirador | Series B | $250M | Jan 2026 |
 Sagimet Biosciences | Series C | $175M | Jan 2026 |
 Aviceda | Series C | — | Jan 2026 |
 Artiva Biotherapeutics | Series B | $120M | Jan 2026 |
 Ambrosia Bio | Series B | $100M | Jan 2026 |
| AAviceda Therapeutics | Unknown | $207.5M | Jan 2026 |
 MapLight Therapeutics | Series D | $372.5M | Jul 2025 |
 Windward Bio | Series A | $200M | Jan 2025 |
| AAviceda Therapeutics | Series C | — | Jan 2025 |
 Windward | Series A | $200M | Jan 2025 |
| Mirador Tx | Series B | $250M | Jan 2025 |
| MMirador Therapeutics | Unknown | $250M | Jan 2025 |
| MapLight Therapeutics | Series D | $372.5M | Jan 2025 |
 Nuvig Therapeutics | Series B | $161M | Dec 2024 |
 Eledon Pharmaceuticals | Unknown | $85M | Oct 2024 |
 Cardurion Pharmaceuticals | Series B | $260M | Jul 2024 |
| Mirador Tx | Unknown | $400M | Mar 2024 |
| Nuvig Therapeutics | Series B | $208M | Jan 2024 |
| PPalvella Therapeutics, Inc. | Series C | $45M | May 2020 |
| Sagimet Biosciences | Series E | $25M | Aug 2019 |
| Windward | Series C | $16.5M | Apr 2015 |
| OObsidian Therapeutics, Inc. | Series A | $160.5M | — |
Top Co-Investors
OrbiMed11 shared
Logos Capital10 shared
Sanofi Ventures9 shared
Farallon Capital Management8 shared
The Invus Group, LLC6 shared
Omega Funds6 shared
Novo Capital6 shared
Digitalis Ventures6 shared
Alexandria Venture Investments5 shared
Boxer Capital5 shared
Moore Strategic Ventures5 shared
ARCH Venture Partners5 shared
Fairmount Funds Management5 shared
RA Capital Management5 shared
Samsara BioCapital4 shared
Novo Holdings A/S4 shared
Blue Owl Capital4 shared
Bristol Myers Squibb3 shared
Last updated: 7 October 2026